Molecular Mechanisms Underlying TDP-43 Pathology in Cellular and Animal Models of ALS and FTLD

Molecular Mechanisms Underlying TDP-43 Pathology in Cellular and Animal Models of ALS and FTLD

Amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) are neurodegenerative disorders that exist on a disease spectrum due to pathological, clinical and genetic overlap. In up to 97% of ALS cases and ~50% of FTLD cases, the primary pathological protein observed in affected...

Full description

Bibliographic Details
Main Authors:	Alistair Wood, Yuval Gurfinkel, Nicole Polain, Wesley Lamont, Sarah Lyn Rea
Format:	Article
Language:	English
Published:	MDPI AG 2021-04-01
Series:	International Journal of Molecular Sciences
Subjects:	amyotrophic lateral sclerosis frontotemporal lobar degeneration TARDBP/TDP-43 RNA metabolism mitochondrial dysfunction proteostasis
Online Access:	https://www.mdpi.com/1422-0067/22/9/4705

Similar Items

A C-Terminally Truncated TDP-43 Splice Isoform Exhibits Neuronal Specific Cytoplasmic Aggregation and Contributes to TDP-43 Pathology in ALS
by: Marc Shenouda, et al.
Published: (2022-06-01)

The Pathobiology of TDP-43 C-Terminal Fragments in ALS and FTLD
by: Britt A. Berning, et al.
Published: (2019-04-01)

Heterogeneity of cortical pTDP-43 inclusion morphologies in amyotrophic lateral sclerosis
by: Rachel H. Tan, et al.
Published: (2023-11-01)

Evidence of cerebellar TDP-43 loss of function in FTLD-TDP
by: Sarah Pickles, et al.
Published: (2022-07-01)

Both cytoplasmic and nuclear accumulations of the protein are neurotoxic in Drosophila models of TDP-43 proteinopathies
by: Laetitia Miguel, et al.
Published: (2011-02-01)

Transcriptomic Analysis of Zebrafish TDP-43 Transgenic Lines
by: Alexandra Lissouba, et al.
Published: (2018-12-01)

TDP-43 mislocalization drives neurofilament changes in a novel model of TDP-43 proteinopathy
by: Rachel Atkinson, et al.
Published: (2021-02-01)

Movement disorders are linked to TDP-43 burden in the substantia nigra of FTLD-TDP brain donors
by: Luigi Fiondella, et al.
Published: (2023-04-01)

Diffuse argyrophilic grain disease with TDP-43 proteinopathy and neuronal intermediate filament inclusion disease: FTLD with mixed tau, TDP-43 and FUS pathologies
by: Shunsuke Koga, et al.
Published: (2023-07-01)

Long noncoding RNAs in TDP-43 and FUS/TLS-related frontotemporal lobar degeneration (FTLD)
by: Guinevere F. Lourenco, et al.
Published: (2015-10-01)

Robustness and Vulnerability of the Autoregulatory System That Maintains Nuclear TDP-43 Levels: A Trade-off Hypothesis for ALS Pathology Based on in Silico Data
by: Akihiro Sugai, et al.
Published: (2018-02-01)

Distinct Phospho-TDP-43 brain distribution in two cases of FTD, one associated with ALS
by: Álvaro C.B. Guedes, et al.

Molecular Mechanisms of TDP-43 Misfolding and Pathology in Amyotrophic Lateral Sclerosis
by: Archana Prasad, et al.
Published: (2019-02-01)

Altered microRNA expression in frontotemporal lobar degeneration with TDP-43 pathology caused by progranulin mutations
by: Kocerha Jannet, et al.
Published: (2011-10-01)

TDP-43 Pathology in Alzheimer’s Disease
by: Axel Meneses, et al.
Published: (2021-12-01)

Physiological tissue-specific and age-related reduction of mouse TDP-43 levels is regulated by epigenetic modifications
by: Miriam Pacetti, et al.
Published: (2022-04-01)

TDP-43 Proteinopathy Specific Biomarker Development
by: Isabell Cordts, et al.
Published: (2023-02-01)

Cerebrospinal Fluid TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis Patients with and without the C9ORF72 Hexanucleotide Expansion
by: Anna Junttila, et al.
Published: (2016-04-01)

Understanding In Vitro Pathways to Drug Discovery for TDP-43 Proteinopathies
by: Hei W. A. Cheng, et al.
Published: (2022-11-01)

Molecular Pathways Involved in Frontotemporal Lobar Degeneration with TDP-43 Proteinopathy: What Can We Learn from Proteomics?
by: Merel O. Mol, et al.
Published: (2021-09-01)

TDP-43 is a ubiquitylation substrate of the SCFcyclin F complex
by: Stephanie L. Rayner, et al.
Published: (2022-06-01)

Alterations in stress granule dynamics driven by TDP-43 and FUS: A link to pathological inclusions in ALS?
by: Anais eAulas, et al.
Published: (2015-10-01)

α-Methyl-α-phenylsuccinimide ameliorates neurodegeneration in a C. elegans model of TDP-43 proteinopathy
by: Shi Quan Wong, et al.
Published: (2018-10-01)

New Antibody-Free Mass Spectrometry-Based Quantification Reveals That C9ORF72 Long Protein Isoform Is Reduced in the Frontal Cortex of Hexanucleotide-Repeat Expansion Carriers
by: Arthur Viodé, et al.
Published: (2018-08-01)

A panel of TDP-43-regulated splicing events verifies loss of TDP-43 function in amyotrophic lateral sclerosis brain tissue
by: Maize C. Cao, et al.
Published: (2023-09-01)

Clinical and neuropathological features of ALS/FTD with TIA1 mutations
by: Veronica Hirsch-Reinshagen, et al.
Published: (2017-12-01)

Neuronal intermediate filament inclusion disease may be incorrectly classified as a subtype of FTLD-FUS
by: Kevin F Bieniek, et al.
Published: (2020-03-01)

The Role of TDP-43 in Military-Relevant TBI and Chronic Neurodegeneration
by: Lanier Heyburn, et al.
Published: (2019-06-01)

Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration
by: Alba Cervantes González, et al.
Published: (2022-04-01)

Transcriptomopathies of pre- and post-symptomatic frontotemporal dementia-like mice with TDP-43 depletion in forebrain neurons
by: Lien-Szu Wu, et al.
Published: (2019-03-01)

An Amyloid-like Pathological Conformation of TDP-43 is Stabilized by Hypercooperative Hydrogen Bonds
by: Miguel Mompeán, et al.
Published: (2016-11-01)

ALS-linked TDP-43M337V knock-in mice exhibit splicing deregulation without neurodegeneration
by: Seiji Watanabe, et al.
Published: (2020-01-01)

Immunotherapy targeting the C-terminal domain of TDP-43 decreases neuropathology and confers neuroprotection in mouse models of ALS/FTD
by: Tariq Afroz, et al.
Published: (2023-04-01)

Targeting the glycine-rich domain of TDP-43 with antibodies prevents its aggregation in vitro and reduces neurofilament levels in vivo
by: Henrick Riemenschneider, et al.
Published: (2023-07-01)

Interrupted CAG expansions in ATXN2 gene expand the genetic spectrum of frontotemporal dementias
by: Clémence Fournier, et al.
Published: (2018-05-01)

Age-dependent neurodegeneration and organelle transport deficiencies in mutant TDP43 patient-derived neurons are independent of TDP43 aggregation
by: N. Kreiter, et al.
Published: (2018-07-01)

Nuclear import receptors are recruited by FG-nucleoporins to rescue hallmarks of TDP-43 proteinopathy
by: Bilal Khalil, et al.
Published: (2022-12-01)

Low T-cell reactivity to TDP-43 peptides in ALS
by: Swetha Ramachandran, et al.
Published: (2023-07-01)

Distinct molecular patterns of TDP-43 pathology in Alzheimer’s disease: relationship with clinical phenotypes
by: Sandra O. Tomé, et al.
Published: (2020-04-01)

Pathological phosphorylation of tau and TDP-43 by TTBK1 and TTBK2 drives neurodegeneration
by: Laura M. Taylor, et al.
Published: (2018-02-01)